Comparative Gastrointestinal Safety of Bisphosphonates in Primary Osteoporosis: a Network Meta-analysis

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2013 Nov 30

PMID 24287510

Citations 18

Authors

M Tadrous

L Wong

M M Mamdani

D N Juurlink

M D Krahn

L E Levesque

S M Cadarette

Affiliations

Soon will be listed here.

Abstract

Unlabelled: We completed a network meta-analysis of published papers to compare bisphosphonate gastrointestinal safety. We found that zoledronic acid had the highest chance of causing gastrointestinal adverse events. Etidronate had the highest chance of discontinuation due to an adverse event. No difference was found for serious adverse events.

Introduction: Bisphosphonates are first-line treatment for osteoporosis. Gastrointestinal (GI) adverse events (AE) are the primary reason for non-adherence. Little is known about the comparative GI safety of bisphosphonates.

Purpose: Leverage published clinical trial data to examine the comparative GI safety of bisphosphonates.

Methods: We completed a systematic review of all English-language clinical trials that assessed bisphosphonate safety and/or efficacy in primary osteoporosis through to 2012. Randomized, blinded, and controlled studies were eligible. The primary outcome was any GI-related AE. Subanalyses were completed for upper GI symptoms, serious GI, nausea, esophageal-related events, and discontinuation due to AE. A Bayesian-based network meta-analysis was completed to allow for indirect comparisons. Results were reported as the probability that a specific drug had the highest number of events.

Results: We identified 50 studies: 32 alendronate, 12 risedronate, 5 etidronate, and 7 zoledronic acid. Zoledronic acid had the highest probability of having the highest number of any GI AE (91%) and nausea (70%). Etidronate (70%) and zoledronic acid (28%) had the highest probability of having the greatest attrition due to AE. Etidronate had the highest probability (56%) of having the greatest number of upper GI symptoms among oral bisphosphonates.

Conclusion: Zoledronic acid had the highest probability of causing the greatest number of GI AE, possibly related to nausea. These results question the assumption that annual zoledronic acid will translate into better adherence. Little difference was found between alendronate and risedronate for serious AE. More research into real-world implications of the comparative safety of bisphosphonates is needed.

Citing Articles

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Peterson J, Zheng C, Kelly S, Shea B Cochrane Database Syst Rev. 2025; 1:CD001155.

PMID: 39868546 PMC: 11770842. DOI: 10.1002/14651858.CD001155.pub3.

Additional effects of herbal medicine combined with bisphosphonates for primary osteoporosis: a systematic review and meta-analysis.

Yoo Y, Kim M, Park H, Chae M, Choi Y, Oh C Front Pharmacol. 2024; 15:1413515.

PMID: 39346562 PMC: 11427380. DOI: 10.3389/fphar.2024.1413515.

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Wells G, Hsieh S, Peterson J, Zheng C, Kelly S, Shea B Cochrane Database Syst Rev. 2024; 4:CD003376.

PMID: 38591743 PMC: 11003221. DOI: 10.1002/14651858.CD003376.pub4.

Pediatric and adult osteoporosis: a contrasting mirror.

Ferjani H, Cherif I, Nessib D, Kaffel D, Maatallah K, Hamdi W Ann Pediatr Endocrinol Metab. 2024; 29(1):12-18.

PMID: 38461801 PMC: 10925787. DOI: 10.6065/apem.2346114.057.

Non-steroidal Anti-inflammatory Drug (NSAID)-, Potassium Supplement-, Bisphosphonate-, and Doxycycline-Mediated Peptic Ulcer Effects: A Narrative Review.

Keller C, Jones N, Abadie R, Barham W, Behara R, Patil S Cureus. 2024; 16(1):e51894.

PMID: 38333496 PMC: 10849936. DOI: 10.7759/cureus.51894.

References

Bobba R, Beattie K, Parkinson B, Kumbhare D, Adachi J . Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf. 2006; 29(12):1133-52. DOI: 10.2165/00002018-200629120-00005. View

Cortet B, Bera-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B . Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy. Joint Bone Spine. 2001; 68(5):410-5. DOI: 10.1016/s1297-319x(01)00297-4. View

Goodman N, Cobin R, Ginzburg S, Katz I, Woode D . American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations. Endocr Pract. 2011; 17(6):949-54. DOI: 10.4158/ep.17.6.949. View

Papaioannou A, Morin S, Cheung A, Atkinson S, Brown J, Feldman S . 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010; 182(17):1864-73. PMC: 2988535. DOI: 10.1503/cmaj.100771. View

Lanza F, Hunt R, Thomson A, Provenza J, Blank M . Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000; 119(3):631-8. DOI: 10.1053/gast.2000.16517. View

Jansen J, Bergman G, Huels J, Olson M . The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis. Semin Arthritis Rheum. 2010; 40(4):275-84.e1-2. DOI: 10.1016/j.semarthrit.2010.06.001. View

Cryer B, Binkley N, Simonelli C, Lewiecki E, Lanza F, Chen E . A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. Am J Geriatr Pharmacother. 2005; 3(3):127-36. DOI: 10.1016/s1543-5946(05)80019-4. View

Curtis J, Yun H, Matthews R, Saag K, Delzell E . Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken). 2012; 64(7):1054-60. PMC: 3355221. DOI: 10.1002/acr.21638. View

Penning-van Beest F, Goettsch W, Erkens J, Herings R . Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006; 28(2):236-42. DOI: 10.1016/j.clinthera.2006.01.002. View

10.

Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W . A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007; 40(5):1238-43. DOI: 10.1016/j.bone.2007.01.016. View

11.

Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, MINAGUCHI H . A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group). Osteoporos Int. 2003; 14(3):225-34. DOI: 10.1007/s00198-002-1369-9. View

12.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A . Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007; 41(1):122-8. DOI: 10.1016/j.bone.2007.03.011. View

13.

Catala-Lopez F, Sanfelix-Gimeno G, Tobias A, Hurtado I, Sanfelix-Genoves J, Peiro S . Efficacy of osteoporosis therapies in a network meta-analysis with indirect comparisons: many concerns for new tools of evidence synthesis?. Osteoporos Int. 2013; 24(6):1927-8. DOI: 10.1007/s00198-013-2294-9. View

14.

Hoaglin D, Hawkins N, Jansen J, Scott D, Itzler R, Cappelleri J . Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011; 14(4):429-37. DOI: 10.1016/j.jval.2011.01.011. View

15.

Adachi J, Faraawi R, OMahony M, Nayar A, Massaad R, Evans J . Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study. Clin Ther. 2009; 31(8):1747-53. DOI: 10.1016/j.clinthera.2009.08.016. View

16.

Jansen J, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N . Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011; 14(4):417-28. DOI: 10.1016/j.jval.2011.04.002. View

17.

Kherani R, Papaioannou A, Adachi J . Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Saf. 2002; 25(11):781-90. DOI: 10.2165/00002018-200225110-00003. View

18.

Downs Jr R, Bell N, Ettinger M, Walsh B, Favus M, Mako B . Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000; 85(5):1783-8. DOI: 10.1210/jcem.85.5.6606. View

19.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V . Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523. DOI: 10.1002/14651858.CD004523.pub3. View

20.

Bone H, Greenspan S, McKeever C, Bell N, Davidson M, Downs R . Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000; 85(2):720-6. DOI: 10.1210/jcem.85.2.6393. View